Sean Browne: Yeah. So there’s nothing — well, we always have a full funnel of new opportunities, right? And a lot of it comes down to timing, evaluation, all the other pieces to that, but I think you’re hitting on both . I think that as an organization, we absolutely want to find where possible similar deals like we have with Coflex, product lines that quite frankly were forgotten or not forgotten, just couldn’t be given the focus at a bigger organization, we’ll take that. And those are things that from an integration perspective and from the implementation and from, quite frankly, what it means to your revenue and earnings can be accretive fairly quickly. So love, love, love, love those deals, and we’ll seek those wherever possible.
When you talk about some capacity expanding opportunities that also bring us potentially into some other biologics, I see those speakers, again, the size of our business, those are a little more transformational. And so absolutely, those are things that are also on the docket. It’s just a matter of, again, finding the right fit and finding what is the right value and all the pieces that go along with that. So without being too cagey, right, I got it, it’s really a matter of prioritization and the deal that comes forward.
Chase Knickerbocker: Got it, it all makes sense. Then last one for you, Scott. Gross margins were up nicely. Just one month of Coflex benefit, you should be up nicely again with a full quarter. Where does the entire business kind of steady out here over the next, let’s say, a couple of quarters through the end of the year from a gross margin perspective?
Scott Neils: I think we saw coming in about mid-57. I think as we progress through the year, I think we’ll start to make our way into the 60s, the low- to mid-60s on the gross margin front.
Chase Knickerbocker: Helpful. All right, thanks, guys, for taking the questions. Nice quarter again, thanks.
Sean Browne: Great. Thanks, Chase.
Operator: Our next question today comes from Kyle Rose of Canaccord.
Sean Browne: Hey, Kyle. How are you, Kyle?
Kyle Rose: Good morning, everyone. Just two quick questions for me. One, you talked about Coflex opening up in non-acute sector. Just wondering how you could think about that in longer-term, and you touched on it in earlier questions, any changes to the different type of distributors you need for that market? And then I’ll just ask the second question now, can you remind us the new product cadence that you have lined up now for biologics? Thank you.
Sean Browne: Sure. Okay. So how are we thinking about Coflex and how then — let me just repeat the question, how we’re thinking about Coflex moving forward and how that helps us in the ambulatory surgery center market / outpatient market? Is that really your question, Kyle?
Kyle Rose: Yeah. And then just the overall strategy different call points.
Sean Browne: Yeah. So when you think about Coflex overall and the fact that it’s really what we’re going after are those — it’s a really robust market and experienced 60,000 plus laminectomies and the 260,000 plus single-level fusions. And so what we have to offer really is a great product that many, if not most of those procedures are moving outside of the hospital. And so we look at Coflex as this great opportunity that not only is a superior product, the fact that’s a superior clinical outcome and that it preserves all alternatives. So if you are somebody who’s about to get a laminectomy, why wouldn’t you get a laminectomy with our Coflex device, which again interlaminar gives you a full range of motion, gives you all the things that you need, and hopefully, stays off fusion for quite some time.
